Drug Profile

Rosuvastatin extended release - Lyndra

Alternative Names: LYN-047

Latest Information Update: 30 May 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Lyndra
Class Antihyperlipidaemics; Fluorobenzenes; Pyrimidines; Small molecules; Sulfonamides
Mechanism of Action HMG-CoA reductase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I Dyslipidaemias

Most Recent Events

30 May 2024 Rosuvastatin extended release is still in phase I trial for Dyslipidaemias in Australia (PO) (Lyndra pipeline, May 2024)
28 Feb 2024 No recent reports of development identified for phase-I development in Dyslipidaemias(In volunteers) in Australia (PO, Capsule)
19 Mar 2021 Lyndra completes a phase I clinical trial in Dyslipidaemias (In volunteers) in Australia (PO)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com